Will the Volume-Based Procurement Policy Promote Pharmaceutical Firms’ R&D Investment in China? An Event Study Approach
Innovation is the key to the development of the pharmaceutical industry. The pilot program of China’s “4 + 7” volume-based procurement policy (“4 + 7” procurement policy) brings the drug price back to a reasonable level through trading procurement quantities for lower drug prices. The policy manages...
Guardado en:
Autores principales: | Yuanyuan Hu, Shouming Chen, Fangjun Qiu, Peien Chen, Shaoxiong Chen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/86786516469944cc815ef8b076a04837 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Extrinsic factors influencing the bid/no-bid decision of construction contracting firms: Impact of firm size and experience
por: Maqsoom,Ahsen, et al.
Publicado: (2020) -
Financing Strategies of New Technology-Based Firms: A Comparison of Women-and Men-Owned Firms
por: Robb,Alicia M, et al.
Publicado: (2010) -
Technological Capability and Firm Performance
por: Reichert,Fernanda Maciel, et al.
Publicado: (2014) -
The Effects of ERM Adoption on European Insurance Firms Performance and Risks
por: Doureige J. Jurdi, et al.
Publicado: (2021) -
The impact of “4 + 7” volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis
por: Ying Yang, et al.
Publicado: (2021)